Current Setup & Catalysts
Current Setup & Catalysts — Onyx Biotec Limited
Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.
1. Current Setup in One Page
Six days ago (14 May 2026) the board signed off the first full year of audited financials as a listed company; the print invalidated the IPO marketing pitch with revenue $7.4M (+10.8%) but a $22K net loss and operating margin of 4.89% versus 16.76% the year before. The tape had already discounted this — the stock sits at $0.33, almost exactly book value ($0.32) and 47.5% below the $0.72 IPO price — and the FY26 print delivered no new shock. The live debate is whether H2 FY26's sequential OPM bounce (2.72% → 7.02%) is the trough or a head-fake. The setup is bearish-but-quiet on a microcap that institutions cannot own, with one hard-dated catalyst that matters: the H1 FY27 half-yearly print due November 2026, which tests whether margin recovery is real or whether FY26 is the new normal.
Hard-dated events in next 6 months
High-impact catalysts
Next hard date (days from today)
*Recent setup: Bearish / Quiet*
One-line setup. FY26 audited results (14 May 2026) confirmed the post-IPO operating reset; with no analyst coverage, no quarterly cadence, and ADV of ~$2.5K, the price-discovery vehicle for the next twelve months is the half-yearly print — and the next one (H1 FY27, ~November 2026) is the only catalyst in the next six months that can move underwriting. Everything else is noise or beyond-six-month context.
2. What Changed in the Last 3–6 Months
The catalogue below is dated, sourced, and ranked by what still shapes today's setup. Three items are inside the strict 3–6 month window (Feb–May 2026); four 12-month items are retained only because they explain why the market is positioned where it is today.
The narrative arc in three lines. Before September 2025 the market still owned the IPO story: $0.63–0.67 print, FY25 OPM 16.4%, MarketsMojo upgrade to "very attractive". After H1 FY26 (13 Nov 2025), the market repriced the operating model — the stock halved to $0.32 by 20 March 2026 — and after FY26 audited (14 May 2026), it stopped repricing because the print was already in. The unresolved question is whether H2 FY26's 7.02% OPM is the base of a recovery (bull) or a fade back to the H1 trough (bear); only the H1 FY27 print, six months out, settles it.
3. What the Market Is Watching Now
The post-FY26 debate has narrowed to four specific data points. Each will be observable inside the next 6–12 months, three of them in a single disclosure (the H1 FY27 board meeting in November 2026).
Three of the four items above land inside two disclosures: the FY26 Annual Report dispatch (likely September 2026) and the H1 FY27 board meeting (~13 November 2026). There is no third meaningful disclosure between today and those two events. That makes the next six months structurally quiet — the calendar itself, not management silence, is the explanation.
4. Ranked Catalyst Timeline
The ranking below is by decision value to a hedge fund: a catalyst earns rank 1 only if its outcome would force underwriting to change, not because it is closer in time. ONYX has no analyst coverage, no maintained consensus, and no concall, so "consensus" is "not visible" almost everywhere — the disclosure itself becomes the consensus.
The single most important catalyst inside six months is item #1: H1 FY27 half-yearly results, November 2026. No analyst publishes a forecast; the implicit baseline is H2 FY26 (revenue $3.72M, OPM 7.02%, debtor days 144). Each of the three gates above — OPM, DSO, CFO sign — has been explicitly named by both bull (re-rate trigger) and bear (cover signal). All three can clear at once; the asymmetry on a microcap with no consensus is that the print itself becomes the consensus.
5. Impact Matrix — What Actually Resolves the Debate
Of the nine catalysts above, only the four below would force a real underwriting change. Everything else adds information; these update durable thesis variables.
The cleanest read of the matrix: only one item (H1 FY27 results) is both decision-relevant and dated inside six months. One item (FY26 AR dispatch) is dated inside six months but lower impact unless it surfaces a receivables-ageing surprise. The two items that would actually change the 10-year underwriting (regulatory dossier; observable Schedule M displacement) are undated and may not arrive at all. A PM who buys here is paying $0.33 — roughly book value — for one binary print in six months and an option on management ever announcing a regulatory capex cheque.
6. Next 90 Days
The 90-day window (today through ~19 August 2026) is genuinely quiet. The FY26 results print already happened (14-May-2026); the FY26 Annual Report dispatch is on the cusp of the window's far edge (FY25 AR dispatched 2-Sep-2025, so FY26 AR likely just outside 90 days); H1 FY27 results are 180 days out. The realistic 90-day catalogue:
- Quarterly shareholding pattern filing — June 2026 (Q1 FY27). Whether promoter holding stays at 65.10% (expected); whether FII holding floors or breaks below 1% (the FII unwind is largely done but a final touch lower is possible); any DII accumulation. Watch: any promoter holding decline at all (none expected; would be a red flag well ahead of the Nov-2027 lock-in).
- CDSCO Schedule M closure data — anytime through August 2026. No scheduled publication date; could surface in industry reports or trade press. Watch: a number above 200 closures in Solan/Baddi puts magnitude on the tailwind for the first time.
- Any NSE corporate announcement — order win, regulatory inspection, capex commitment. Frequency has been ~1 material disclosure per 4–6 weeks since IPO (mostly contract additions); none would re-rate the equity unless it names an EU-GMP / USFDA filing or a regulated-market customer.
- Innova Captab Q1 FY27 results — early August 2026. The closest like-for-like peer; Kathua block utilisation read-through is the cleanest off-filing signal for Onyx's Unit II competitive position.
- Bulk-deal disclosures — rolling. With FII near zero and the next promoter lock-in 18 months away, any bulk deal of size would be a fresh signal. None expected at current volumes (~$2.5K ADV).
The 90-day window is structurally thin. No earnings, no AGM, no concall, no analyst day. A PM watching this name through the summer should expect no decision-grade disclosure until the FY26 AR dispatch in early September 2026 — and the real underwriting test is the H1 FY27 print in mid-November 2026.
7. What Would Change the View
The two observable signals that would most change the investment debate over the next six months are (1) the H1 FY27 OPM print and (2) the FY26 receivables-ageing schedule. The first is the single largest near-term test of the Long-Term Thesis margin-recovery driver (#3 Unit II ramp, #6 cash conversion) — a print of OPM ≥10%, debtor days <130, and positive CFO would support the bull's "trough is in" frame and partially close the forensic gap on cash conversion; a print of OPM <7%, debtor days >145, and negative CFO would point the other way, weakening the asset-floor anchor and aligning the setup with the bear's $0.21 adjusted-book target. The second — the receivables ageing schedule that the FY26 annual report should disclose for the first time at full granularity — directly tests the forensic concern that $5.4M of "other current assets" hides impairment; a benign ageing distribution (90% under 90 days) would lift the book-value floor, while >180-day buckets above 10% of total would prompt an impairment scenario consistent with stated book moving from $0.32 toward $0.23–0.27. Beyond those two, the multi-year underwriting question (Long-Term Thesis driver #4) is still about whether management ever announces a regulated-market dossier filing — a signal that has not arrived, is not scheduled, and whose absence through FY2028 would be the strongest single refutation of the compounder case. None of the other items on the timeline — peer signals, bulk deals, governance routine — would change the view on their own, though any could compound a negative signal from the two primary tests.